This pilot study will assess the safety and feasibility of intravenous (IV) ketamine combined with RO DBT in young adults with Treatment-Resistant Depression (TRD). In addition, this study will develop and utilize innovative methodological approaches to demonstrate the feasibility of precision medicine with this type of therapy.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
16
The participant will receive 4 weeks of 0.5mg/kg intravenous ketamine given over 40 minutes, as is routinely done in ketamine treatment and four months of RO DBT treatment.
Washington University School of Medicine
St Louis, Missouri, United States
Remission from Depression
Remission defined as Montgomery and Asberg Depression Rating Scale (MADRS) score ≤10. Scale ranges from 0-60 with higher scores indicating higher depression severity.
Time frame: Approximately 5 months
Visual analogue scale of depressive and anxiety symptoms
Asses daily changes in symptoms following ketamine infusions and RODBT sessions
Time frame: Daily following ketamine and therapy sessions during 4 weeks of ketamine-assisted RO DBT
RewP
The RewP is a neural marker of reward responding and is EEG based. It will examine change id-treatment (Post Ketamine) and post treatment
Time frame: Approximately 5 months
ERN
The ERN is a neural marker of error monitoring and is EEG based. It will examine mechanistic change mid-treatment (post ketamine) and post-treatment.
Time frame: Approximately 5 months
SCS-R and UCLA Loneliness Scale
The Social Connectedness SCale Revised (SCS-R) and the UCLA loneliness scale measure social connectedness (or lack of) via self-report. They will examine mechanistic change mid-treatment (post ketamine) and post-treatment.
Time frame: Approximately 5 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.